Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials

SIMPLE SUMMARY: Secondary acute myeloid leukemia (s-AML) refers to the development of AML following myelodysplatic syndrome or other hematological malignancies, or after a solid tumors, or nonmalignant diseases or following exposure to environmental or occupational carcinogens. Here, we report data...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramadan, Safaa M., Suciu, Stefan, Stevens-Kroef, Marian J. P. L., Willemze, Roelof, Amadori, Sergio, de Witte, Theo, Löwenberg, Bob, Muus, Petra, Labar, Boris, Meert, Liv, de Schaetzen, Gaetan, Meloni, Giovanna, Leone, Giuseppe, Vignetti, Marco, Marie, Jean-Pierre, Lübbert, Michael, Baron, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697114/
https://www.ncbi.nlm.nih.gov/pubmed/33187229
http://dx.doi.org/10.3390/cancers12113334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697114/
https://www.ncbi.nlm.nih.gov/pubmed/33187229
http://dx.doi.org/10.3390/cancers12113334

Ejemplares similares